Rolls-Royce Holdings plc (FRA:RRU)

Revance Therapeutics Revenue

Rolls-Royce Holdings had revenue of 9.49B GBP in the half year ending June 30, 2025, with 26.15% growth. This brings the company's revenue in the last twelve months to 19.54B, up 9.62% year-over-year. In the year 2024, Rolls-Royce Holdings had annual revenue of 18.91B with 14.70% growth.

• Revenue (ttm): 19.54B GBP
• Revenue Growth: +9.62%
• P/S Ratio: 4.56
• Revenue / Employee: 460.80K GBP
• Employees: 42,400
• Market Cap: 103.91B USD

Revenue Chart

* This company reports financials in GBP.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	18.91B	2.42B	14.70%
Dec 31, 2023	16.49B	2.97B	21.94%
Dec 31, 2022	13.52B	2.30B	20.52%
Dec 31, 2021	11.22B	-273.00M	-2.38%
Dec 31, 2020	11.49B	-5.10B	-30.72%